For Patients and Caregivers

Are you considering incorporating OCREVUS ZUNOVO
into your practice workflow?

OCREVUS ZUNOVO may be administered in multiple sites of treatment, including clinics without IV infusion capabilities

Start strong with the only ~10-minute,* 2X-yearly, HCP-administered† subcutaneous injection that offers1:

Icon of a checkmark in a circle

NO split first dose

Icon of a checkmark in a circle

NO dilution

Icon of a checkmark in a circle

NO IV infusion–specific supplies needed

If practices would like to incorporate OCREVUS ZUNOVO into their workflow, there will be some updates to logistics and processes for your practice. Choose a category in the quick links at the top of this page to review some of the unique considerations to keep in mind once your organization has decided to begin prescribing OCREVUS ZUNOVO for your patients.

DO NOT DELETE - this is only visible on author and provides the anchor for the video, offset to compensate for the mobile masthead and sticky nav

*Does not include all aspects of the treatment. Actual injection time may vary.
†HCP = healthcare professional

OCREVUS ZUNOVO samples are available

A free sample dose‡ allows prescribing HCPs to become familiar with OCREVUS ZUNOVO and start building experience for eligible patients with MS

Contact Your Genentech Representative

‡Drug samples may not be sold, purchased, traded or offered for sale, purchase or trade, utilized to seek reimbursement or otherwise distributed in a manner not permitted by applicable law. Samples may only be distributed to practitioners who are licensed or authorized under applicable state law to prescribe the drug product and whose practices are relevant to the FDA-approved product labeling for OCREVUS ZUNOVO. Distribution of the sample does not obligate use or continuing use of OCREVUS ZUNOVO.You may not advertise or otherwise use the program as a means of promoting your services or Genentech’s products to patients. Genentech reserves the right to deny fulfillment of the sample to anyone deemed ineligible in accordance with stated program criteria. Annual sample limits per HCP and brand apply.

ADMINISTRATION TIME

OCREVUS ZUNOVO administration time

With a shorter administration time than OCREVUS® [IV] and no split first dose, 2X-yearly OCREVUS ZUNOVO offers scheduling flexibility for your patients and practice

OCREVUS ZUNOVO offers ~10-minute* HCP-administered subcutaneous (SC) injection with no split first dose
  • OCREVUS ZUNOVO is for subcutaneous use in the abdomen only
  • OCREVUS ZUNOVO has different dosage and administration instructions than intravenous ocrelizumab
  • OCREVUS ZUNOVO should be administered via subcutaneous injection by an HCP

*Does not include all aspects of treatment. Actual injection time may vary.
†Injection time may be longer if the treatment is interrupted.
‡For all doses, post-injection observation with access to appropriate medical support to manage severe injection reactions is recommended.

OCREVUS ZUNOVO VS OCREVUS [IV]

What’s unique about OCREVUS ZUNOVO vs OCREVUS [IV]?

 

What's the same?

What's unique?
Genentech support
  • Patient Navigators
  • OCREVUS Access Solutions
  • Patient financial assistance programs*
  • Support program enrollment process (OCREVUS Start Form)
  • Patient one-on-one supplemental education
  • OCREVUS ZUNOVO Starter Program†
  • OCREVUS ZUNOVO Sampling Program‡
  • OCREVUS ZUNOVO injection training via experiential demonstration
Administration
  • HCP-administered
  • No reconstitution
  • Subcutaneous administration
  • Administration time
  • Post-dose observation time after first injection
  • No split first dose
  • No reconstitution/dilution
  • Ancillary supplies
  • Potential to use syringe pump§
Scheduling
  • Ability to administer in-office or via home health
  • Ability to refer to alternate treatment centers
  • Total treatment time
  • No infusion-specific setting needed
  • First dose is not split between 2 appointments
Acquisition
  • Available via authorized distributors and specialty pharmacies
  
Benefit type
  • Mainly covered under the medical benefit
  
Claims submission
  • ICD-10-CM codes
  • HCPCS codes
  • NDCs
  • CPT administration codes
Payer Coverage
  • Genentech's commitment to parity access to preserve patient and provider choice
  • 85% of patients now covered for OCREVUS ZUNOVO║
Icon of a phone with ellipses in a speech bubble

Contact your Genentech representative to learn more about our patient support programs.

Contact Your Genentech Representative

*Each option has its own eligibility criteria that must be met for patients to receive assistance.
†Subject to eligibility requirements and terms and conditions. This program is void where prohibited by law and may not be used in or by residents of restricted states, if applicable.
‡A free sample dose allows you to become familiar with OCREVUS ZUNOVO and start building experience for your eligible patients with MS. OCREVUS ZUNOVO sample doses must be used according to the approved indications.
§The B. Braun Perfusor® Space Syringe Pump was used in the OCARINA II clinical trial. Genentech does not endorse or recommend any particular pumps. Please refer to the syringe pump manufacturer’s instructions for the most up-to-date information and to ensure appropriate use of any drug or device.
║MMIT medical lives as of [ ] 2025. Individual plans may vary. This information is subject to change without notice. Please check with individual payers for plan-specific requirements.

PRE-PRESCRIPTION & ACQUISITION

EHR & practice management system updates

As one of the key tools for decision-making and process in the practice, it is important to integrate OCREVUS ZUNOVO into your EHR system to enable HCPs to consider it for their appropriate patients

Icon of a checkmark in a circle

Considerations for your practice

  • Ensure your organization’s IT staff and EHR and/or practice management systems vendors have updated your:
    • Order
    • Billing software
    • If you anticipate having eligible patients use the program, load the OCREVUS Co-pay Program Payer ID (82694) into your system*
    • Appointment scheduling tools
    • Other necessary systems
  • Notify and train appropriate staff as needed once all updates are made
Icon of a i in a circle

Additional considerations

Consider adding OCREVUS ZUNOVO to the same dropdown fields in the EHR where OCREVUS [IV] appears today.

OCREVUS ZUNOVO has the same specialty distributor and specialty pharmacy networks as OCREVUS [IV]

Icon of a checkmark in a circle

Considerations for your practice

  • Determine how to acquire OCREVUS ZUNOVO (e.g., purchasing through a specialty distributor or specialty pharmacy)
  • Stay up-to-date on your product inventory
  • OCREVUS ZUNOVO is priced at annual wholesale acquisition cost (WAC) parity with OCREVUS [IV]. Please check with your distributors for the latest information on purchase pricing
Icon of a i in a circle

Additional considerations

  • Consider your organization’s procedure for procuring HCP-administered injectables when determining how to acquire OCREVUS ZUNOVO
  • An OCREVUS Patient Navigator can help you determine if your patient’s health insurance plan requires a specific acquisition method, or if you have a choice

EHR=Electronic health record

*Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their medicine and/or administration of their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.

ADMINISTRATION LOGISTICS

Ancillary supplies

Supplies needed for OCREVUS ZUNOVO administration are not co-packaged with the vial and may take time to acquire. Contact your distributor to learn more about purchasing the injection supplies

You also have the option of using a syringe pump in lieu of the manual injection.

Syringe pump specifications*:

Occlusion limit compatible with

  • 30 mL to 60 mL syringe size
  • Flow rate capability of 1 mL to 5 mL/min

In the OCARINA II study, the instructions called for the occlusion alarm to be set to greater than 6 psi, high, or the least sensitive equivalent setting

Icon of a butterfly syringe

LIVE demonstrations of OCREVUS ZUNOVO manual administration are available from your OCREVUS representative

Contact Your Genentech Representative

*The B. Braun Perfusor® Space Syringe Pump was used in the OCARINA II clinical trial. Genentech does not endorse or recommend any particular pumps. Please refer to the syringe pump manufacturer’s instructions for the most up-to-date information and to ensure appropriate use of any drug or device.

Storing OCREVUS ZUNOVO

OCREVUS ZUNOVO has the same storage needs as OCREVUS [IV].

Icon of a refrigerator
Ensure you have adequate refrigeration space to accommodate the vials needed for patient treatments when they are scheduled. The carton dimensions are 53 × 64 × 87 mm (W × D × H).
Icon of a thermometer
Store OCREVUS ZUNOVO vials at 2 °C to 8 °C (36 °F to 46 °F) in the original carton to protect from light.
Icon of a clock, with text reading "12 hours"
If necessary, OCREVUS ZUNOVO can be removed and placed back into the refrigerator. The total combined time out of the refrigerator of the OCREVUS ZUNOVO vial must not exceed 12 hours at ≤25 °C (77 °F).
Icon of a refrigerator with text reading "72 hr" side by side with and a thermometer with text reading "8 hr"
If not used immediately, the closed syringe can be refrigerated (2 °C to 8 °C [36 °F to 46 °F]) for up to 72 hours followed by 8 hours at ambient temperatures at or below 25 °C (77 °F) in diffuse daylight.
Icon of an i in a speech bubble

If a Genentech product purchase for use in an FDA-approved indication was spoiled, and no product was administered, the product may be eligible for a replacement through the Genentech Spoilage Program†

†The Genentech Spoilage Replacement Program provides for replacement of infused, injected and self-administered products, which are prescribed and prepared for a labeled indication, yet not administered due to unforeseen patient clinical circumstances, subject to certain limitations and conditions set forth by Genentech. The purpose of the programis to support our commitment to protecting patient safety by preventing the use of spoiled, damaged or contaminated products.

Staff training & treatment scheduling

There may be additional considerations for staff training and treatment scheduling, as administration of OCREVUS ZUNOVO differs from OCREVUS [IV].

Icon of a checkmark in a circle

Considerations for your practice when training staff

  • Identify qualified medical personnel at the office to perform the injection; they must be able to administer a complex biologic like OCREVUS ZUNOVO
  • Ensure relevant staff are trained on appropriate subcutaneous administration of OCREVUS ZUNOVO

Considerations when scheduling patients

  • The need for dedicated space for administration, such as an exam room or infusion chair
    • If you have an open layout, consider ways you might accommodate the need for patient privacy
  • The impact of total treatment time on nurse/administration personnel bandwidth
  • The number of schedule blocks available and how many patients you may be able to schedule based on total treatment time
  • Whether your organization’s or the payer’s policies allow you to schedule administration on the same day as an office visit, and the billing documentation logistics involved
DO NOT DELETE - this is only visible on author and provides the anchor for the video, offset to compensate for the mobile masthead and sticky nav

Pretreatment counseling

Before their OCREVUS ZUNOVO injection, be sure to discuss treatment with patients so they know what to expect.

Topics to discuss with patients:

  • Remind patients to bring their health insurance card and other documentation if needed and notify you of any changes to their insurance
  • Let patients know they may want to bring activities to help them pass the time, as well as water, food, snacks or gum (if your facility allows them)
  • Remind patients to wear loose-fitting clothing that allows for ease of access for injection into the abdomen

Oral premedications

Although patients must take the same types of premedications as they do for OCREVUS [IV], the premedications for OCREVUS ZUNOVO are administered orally.

Icon of a clock with text reading "30 minutes"
Administer at least 30 minutes prior to each OCREVUS ZUNOVO administration
20 mg dexamethasone (or equivalent corticosteroid)
An antihistamine (e.g., desloratadine)
The addition of an antipyretic (e.g., acetaminophen) may also be considered
Icon of an i in a speech bubble

Oral premedications can be taken at home or in office, subject to the prescribing physician’s discretion. Consider how the patient has been instructed to take the premedications by their prescriber prior to the scheduled visit.

Post-dose observation

For the initial dose, patients should be observed for at least one hour post-injection. For subsequent doses, patients should be observed for at least 15 minutes post-injection. Patients should be monitored closely during injections, with access to appropriate medical support to manage severe injection reactions.

Icon of a checkmark in a circle

Considerations for your practice

  • Identify where the patient will be observed during the post-dose observation—this may be in the same room as the administration or another area depending on your office setup
  • Patients should be observed for injection reactions, including but not limited to:
    • Local reactions such as erythema, pain, swelling or pruritus
    • Systemic reactions such as headache or nausea
  • Ensure access to and provide appropriate supportive or symptomatic treatment as necessary
Icon of a i in a circle

Please note

In the clinical trial (OCARINA II), all injection reactions were of mild or moderate severity. Most injection reactions required no treatment and all that occurred were resolved.

CPT=Current Procedural Terminology; FDA=US Food and Drug Administration; HCP=healthcare professional; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; IV=intravenous.

NEXT: Support Programs

 

Important Safety Information & Indications

Indications

OCREVUS and OCREVUS ZUNOVO are indicated for the treatment of:

  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • Primary progressive MS, in adults.
Contraindications

Treatment with ocrelizumab is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening administration reactions to ocrelizumab. OCREVUS ZUNOVO is also contraindicated in patients with a history of hypersensitivity to ocrelizumab, hyaluronidase, or any component of OCREVUS ZUNOVO.

Warnings and Precautions
Injection Reactions (OCREVUS ZUNOVO) OR Infusion Reactions (OCREVUS)

OCREVUS ZUNOVO can cause injection reactions, which can be local or systemic. Common symptoms of local injection reactions reported by patients treated with OCREVUS ZUNOVO in multiple sclerosis (MS) clinical trials included erythema, pain, swelling, and pruritus. Common symptoms of systemic injection reactions reported by patients included headache and nausea. In an open-label, active-controlled trial, injection reactions were more frequently reported with the first injection; 49% of patients experienced an injection reaction with the first injection.

In OCREVUS MS clinical trials, the incidence of infusion reactions in patients [who received methylprednisolone (or an equivalent steroid) and possibly other pre-medication to reduce the risk of infusion reactions prior to infusion] was 34% to 40%, with the highest incidence with the first infusion. There were no fatal infusion reactions, but 0.3% of intravenous ocrelizumab-treated MS patients experienced infusion reactions that were serious, some requiring hospitalization. Symptoms of infusion reactions can include pruritus, rash, urticaria, erythema, bronchospasm, throat irritation, oropharyngeal pain, dyspnea, pharyngeal or laryngeal edema, flushing, hypotension, pyrexia, fatigue, headache, dizziness, nausea, tachycardia, and anaphylaxis.

Monitor OCREVUS ZUNOVO patients during and after injections. Observe patients treated with OCREVUS for infusion reactions during the infusion and for at least one hour after completion of the infusion. Inform patients that administration reactions can occur during or within 24 hours of treatment.

Reducing the Risk and Managing Injection or Infusion Reactions

For OCREVUS ZUNOVO, administer oral pre-medication (e.g., dexamethasone or an equivalent corticosteroid, and an antihistamine) at least 30 minutes prior to each OCREVUS ZUNOVO injection to reduce the risk of injection reactions. The addition of an antipyretic (e.g., acetaminophen) may also be considered.

For OCREVUS, administer pre-medication (e.g., methylprednisolone or an equivalent corticosteroid, and an antihistamine) to reduce the frequency and severity of infusion reactions. The addition of an antipyretic (e.g., acetaminophen) may also be considered.

Management recommendations depend on the type and severity of the reaction. For life-threatening reactions, immediately and permanently stop OCREVUS ZUNOVO or OCREVUS and administer appropriate supportive treatment. For less severe OCREVUS ZUNOVO injection reactions, the injection should be interrupted immediately, and the patient should receive symptomatic treatment. The injection should be completed at the healthcare provider’s discretion and only after all symptoms have resolved. For less severe OCREVUS infusion reactions, management may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.

Infections

Serious, including life-threatening or fatal, bacterial, viral, parasitic and fungal infections have been reported in patients receiving ocrelizumab. An increased risk of infections (including serious and fatal bacterial, fungal, and new or reactivated viral infections) has been observed in patients during and following completion of treatment with anti-CD20 B-cell depleting therapies.

A higher proportion of OCREVUS-treated patients experienced infections compared to patients taking REBIF or placebo. In RMS trials, 58% of OCREVUS-treated patients experienced one or more infections compared to 52% of REBIF-treated patients. In the PPMS trial, 70% of OCREVUS-treated patients experienced one or more infections compared to 68% of patients on placebo. OCREVUS was not associated with an increased risk of serious infections in MS patients in controlled trials.

Ocrelizumab increases the risk for upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes-related infections. Delay administration of ocrelizumab in patients with an active infection until the infection has resolved.

Respiratory Tract Infections

A higher proportion of OCREVUS-treated patients experienced respiratory tract infections compared to patients taking REBIF or placebo. In RMS trials, 40% of OCREVUS-treated patients experienced upper respiratory tract infections compared to 33% of REBIF-treated patients, and 8% of OCREVUS-treated patients experienced lower respiratory tract infections compared to 5% of REBIF-treated patients. In the PPMS trial, 49% of OCREVUS-treated patients experienced upper respiratory tract infections compared to 43% of patients on placebo, and 10% of OCREVUS-treated patients experienced lower respiratory tract infections compared to 9% of patients on placebo. The infections were predominantly mild to moderate and consisted mostly of upper respiratory tract infections and bronchitis.

Herpes

In active-controlled (RMS) clinical trials, herpes infections were reported more frequently in OCREVUS-treated patients than in REBIF-treated patients, including herpes zoster (2.1% vs. 1.0%), herpes simplex (0.7% vs. 0.1%), oral herpes (3.0% vs. 2.2%), genital herpes (0.1% vs. 0%), and herpes virus infection (0.1% vs. 0%). Infections were predominantly mild to moderate in severity. In the placebo-controlled (PPMS) clinical trial, oral herpes was reported more frequently in the OCREVUS-treated patients than in the patients on placebo (2.7% vs. 0.8%).

Serious cases of infections caused by herpes simplex virus and varicella zoster virus, including central nervous system infections (encephalitis and meningitis), intraocular infections, and disseminated skin and soft tissue infections, have been reported in the postmarketing setting in multiple sclerosis patients receiving ocrelizumab. Serious herpes virus infections may occur at any time during treatment with ocrelizumab. Some cases were life-threatening.

If serious herpes infections occur, treatment with ocrelizumab should be discontinued or withheld until the infection has resolved, and appropriate treatment should be administered.

Hepatitis B Virus Reactivation

Hepatitis B virus (HBV) reactivation has been reported in MS patients treated with ocrelizumab in the postmarketing setting. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with ocrelizumab. Do not administer ocrelizumab to patients with active HBV confirmed by positive results for HBsAg and anti-HB tests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment.

Possible Increased Risk of Immunosuppressant Effects With Other Immunosuppressants

When initiating treatment with ocrelizumab after an immunosuppressive therapy or initiating an immunosuppressive therapy after ocrelizumab-containing products, consider the potential for increased immunosuppressive effect. Treatment with ocrelizumab has not been studied in combination with other MS therapies.

Vaccinations

Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of ocrelizumab treatment for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of ocrelizumab treatment for non-live vaccines. Ocrelizumab may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines following treatment with ocrelizumab has not been studied, and vaccination with live-attenuated or live vaccines is not recommended during treatment and until B-cell repletion.

Vaccination of Infants Born to Mothers Treated With Ocrelizumab Products During Pregnancy

In infants of mothers exposed to ocrelizumab during pregnancy, do not administer live or live-attenuated vaccines before confirming the recovery of B-cell counts as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines.

You may administer non-live vaccines, as indicated, prior to recovery from B-cell depletion, but you should consider assessing vaccine immune responses, including consultation with a qualified specialist, to assess whether a protective immune response was mounted.

Progressive Multifocal Leukoencephalopathy

Cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients with MS treated with ocrelizumab in the postmarketing setting. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in patients who are immunocompromised, and that usually leads to death or severe disability. PML has occurred in ocrelizumab-treated patients who had not been treated previously with natalizumab, (which has a known association with PML), were not taking any immunosuppressive or immunomodulatory medications associated with risk of PML prior to or concomitantly with ocrelizumab and did not have any known ongoing systemic medical conditions resulting in compromised immune system function.

JCV infection resulting in PML has also been observed in patients treated with other anti-CD20 antibodies and other MS therapies.

At the first sign or symptom suggestive of PML, withhold treatment with ocrelizumab-containing products and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. 

Magnetic resonance imaging (MRI) findings may be apparent before clinical signs or symptoms of PML. Monitoring with MRI for signs consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present. If PML is confirmed, treatment with ocrelizumab should be discontinued.

Reduction in Immunoglobulins

As expected with any B-cell depleting therapy, decreased immunoglobulin levels are observed with ocrelizumab treatment. The pooled data of OCREVUS clinical studies (RMS and PPMS) and their open-label extensions (up to approximately 7 years of exposure) have shown an association between decreased levels of immunoglobulin G (IgG<LLN) and increased rates of serious infections. Monitor the levels of quantitative serum immunoglobulins during treatment with ocrelizumab and after discontinuation of treatment, until B-cell repletion, and especially in the setting of recurrent serious infections. Consider discontinuing treatment with ocrelizumab in patients with serious opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

Malignancies

An increased risk of malignancy with ocrelizumab may exist. In controlled trials, malignancies, including breast cancer, occurred more frequently in OCREVUS-treated patients. Breast cancer occurred in 6 of 781 females treated with OCREVUS and none of 668 females treated with REBIF or placebo. Patients should follow standard breast cancer screening guidelines.

Immune-Mediated Colitis

Immune-mediated colitis, which can present as a severe and acute-onset form of colitis, has been reported in patients receiving ocrelizumab in the postmarketing setting. Some cases of colitis were serious, requiring hospitalization, with a few patients requiring surgical intervention. Systemic corticosteroids were required in many of these patients. The time from treatment initiation to onset of symptoms in these cases ranged from a few weeks to years. Monitor patients for immune-mediated colitis during ocrelizumab treatment and evaluate promptly if signs and symptoms that may indicate immune-mediated colitis, such as new or persistent diarrhea or other gastrointestinal signs and symptoms, occur.

Liver Injury

Clinically significant liver injury, without findings of viral hepatitis, has been reported in the postmarketing setting in patients treated with anti-CD20 B-cell depleting therapies approved for the treatment of MS, including ocrelizumab. Signs of liver injury, including markedly elevated serum hepatic enzymes with elevated total bilirubin, have occurred from weeks to months after administration.

Patients treated with ocrelizumab found to have an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3x the upper limit of normal (ULN) with serum total bilirubin greater than 2x ULN are potentially at risk for severe drug-induced liver injury.

Obtain liver function tests prior to initiating treatment with ocrelizumab, and monitor for signs and symptoms of any hepatic injury during treatment. Measure serum aminotransferases, alkaline phosphatase, and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine, or jaundice. If liver injury is present and an alternative etiology is not identified, discontinue ocrelizumab.

Use in Specific Populations
Pregnancy

There are no adequate data on the developmental risk associated with use of ocrelizumab in pregnant women. There are no data on B-cell levels in human neonates following maternal exposure to ocrelizumab-containing products. However, transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 antibodies during pregnancy. Ocrelizumab is a humanized monoclonal antibody of an immunoglobulin G1 subtype and immunoglobulins are known to cross the placental barrier.

Lactation

There are no data on the presence of ocrelizumab or hyaluronidase in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Ocrelizumab was excreted in the milk of ocrelizumab-treated monkeys. Human IgG is excreted in human milk, and the potential for absorption of ocrelizumab to lead to B-cell depletion in the infant is unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ocrelizumab and any potential adverse effects on the breastfed infant from ocrelizumab or from the underlying maternal condition.

Females and Males of Reproductive Potential

Women of childbearing potential should use effective contraception while receiving ocrelizumab and for 6 months after the last dose of ocrelizumab. Instruct patients that if they are pregnant or plan to become pregnant while taking OCREVUS or OCREVUS ZUNOVO, they should inform their healthcare provider.

Most Common Adverse Reactions

In patients treated with OCREVUS:

  • RMS: The most common adverse reactions (≥10% and >REBIF): upper respiratory tract infections and infusion reactions
  • PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections

The most common adverse reaction observed with OCREVUS ZUNOVO in patients with RMS and PPMS was injection reactions (incidence of 49%).

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information throughout and click here for full OCREVUS Prescribing Information and Medication Guide. For OCREVUS ZUNOVO, click here for full Prescribing Information and Medication Guide.

    • OCREVUS ZUNOVO [prescribing information]. South San Francisco, CA: Genentech, Inc. 2025.

      OCREVUS ZUNOVO [prescribing information]. South San Francisco, CA: Genentech, Inc. 2025.

    • OCREVUS [prescribing information]. South San Francisco, CA: Genentech, Inc. 2025.

      OCREVUS [prescribing information]. South San Francisco, CA: Genentech, Inc. 2025.

    • Data on file. Genentech, Inc. November 2023.

      Data on file. Genentech, Inc. November 2023.

    • Data on file. Genentech, Inc. August 2023.

      Data on file. Genentech, Inc. August 2023.